Abbott Cited For Assay IDE Violations In Nov. 5 FDA Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
Abbott Labs has hired a third-party auditor to assess premarket approval applications for three assays under review by FDA, following the discovery of investigational device exemption violations during a recent bioresearch monitoring inspection conducted by the agency.